Alnylam Reports Publication Of Results From APOLLO-B Phase 3 Study Of Patisiran In Patients With Cardiomyopathy Of ATTR Amyloidosis In The New England Journal Of Medicine
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals has published the results of its APOLLO-B Phase 3 study of Patisiran in patients with Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine. The results of the study could have significant implications for the company's future.
October 25, 2023 | 9:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alnylam Pharmaceuticals has published the results of its APOLLO-B Phase 3 study of Patisiran. The results could potentially impact the company's stock in the short term.
The publication of the results of a Phase 3 study is a significant event for a pharmaceutical company. Positive results can lead to regulatory approval and commercialization of the drug, which can significantly increase the company's revenues. Therefore, this news is highly relevant and important for Alnylam Pharmaceuticals and its investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100